OBIO announced the release of ‘Leading the Pack: Accelerating the Success of the Canadian Health Science Industry.’
The report is based on a comprehensive industry consultation with company executives and leaders from coast-to-coast, who provided their feedback on their experiences in 2020 and recommendations for how Canada’s health science industry can become a global leader in the bioeconomy.
Beyond the enormous disruption caused by the global pandemic, the health science industry has the opportunity to become a pillar of the economy in the long term and it has the potential to create value by addressing all aspects of human health.
Today, the sector contributes only 0.45% to Canada’s total GDP, which is about ten-fold smaller than the contribution of the U.S. industry to its national GDP. There is considerable opportunity for Canada to take a bigger slice of the global bioscience market and for the domestic health science industry to increase its contribution to the Canadian economy.
To accomplish this, capital attraction and driving adoption are the two clear priorities for action articulated by survey and interview respondents. If the twin challenges of capital attraction and driving adoption are addressed, Canada has the potential to become a global leader of innovation and production in healthcare.
Watch the ‘Leading the Pack’ Report Launch Event
On Oct 29th, OBIO launched ‘Leading the Pack: Accelerating the Success of the Canadian Health Science Industry’ at an online event featuring industry leaders providing their insight and experience.
Thank you to Jeremy Bridge-Cook, CEO, Rna Diagnostics; Joe Eibl, CEO, Flosonics Medical; Scott Phillips, Founder and CEO, Starfish Medical; and David Young, Co-founder and CEO, KisoJi Biotechnology.